China’s Hua Medicine plans to list in Hong Kong to raise money for the development of its diabetes treatment. One story has found that some 47 per cent of the Chinese adult population was estimated to have either diabetes or prediabetes. Photo: Alamy China’s Hua Medicine plans to list in Hong Kong to raise money for the development of its diabetes treatment. One story has found that some 47 per cent of the Chinese adult population was estimated to have either diabetes or prediabetes. Photo: Alamy
China’s Hua Medicine plans to list in Hong Kong to raise money for the development of its diabetes treatment. One story has found that some 47 per cent of the Chinese adult population was estimated to have either diabetes or prediabetes. Photo: Alamy

IPO

Business /  Companies

Chinese diabetes drug maker Hua Medicine is second firm to seek Hong Kong IPO under new rules

Company aims to raise some US$200 million to develop drug to lower blood glucose levels

Topic |   IPO
Eric Ng
Eric Ng

Updated: 10:47pm, 6 Jun, 2018

Why you can trust SCMP
China’s Hua Medicine plans to list in Hong Kong to raise money for the development of its diabetes treatment. One story has found that some 47 per cent of the Chinese adult population was estimated to have either diabetes or prediabetes. Photo: Alamy China’s Hua Medicine plans to list in Hong Kong to raise money for the development of its diabetes treatment. One story has found that some 47 per cent of the Chinese adult population was estimated to have either diabetes or prediabetes. Photo: Alamy
China’s Hua Medicine plans to list in Hong Kong to raise money for the development of its diabetes treatment. One story has found that some 47 per cent of the Chinese adult population was estimated to have either diabetes or prediabetes. Photo: Alamy
READ FULL ARTICLE